Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab

Br J Dermatol. 2019 Feb;180(2):419-420. doi: 10.1111/bjd.17320. Epub 2018 Nov 22.

Authors

P Bonnet¹, M Battistella², M Roelens³, C Ram-Wolff¹, F Herms¹, L Frumholtz¹, J-D Bouaziz¹, P Brice⁴, H Moins-Teisserenc³, M Bagot¹, A de Masson¹

Affiliations

¹ Department of Dermatology, Saint-Louis Hospital, INSERM U976, Paris Diderot University, 1 avenue Claude Vellefaux, 75010, Paris, France.
² Department of Pathology, Saint-Louis Hospital, Paris Diderot University, Paris, France.
³ Department of Immunology and Histocompatibility, INSERM U1160, Institut Universitaire d'Hématologie, Paris Diderot University, Paris, France.
⁴ Department of Hemato-oncology, Saint-Louis Hospital, Paris Diderot University, Paris, France.

PMID: 30328116
DOI: 10.1111/bjd.17320

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Autoimmunity / drug effects*
Female
Humans
Middle Aged
Receptors, CCR4 / antagonists & inhibitors
Receptors, CCR4 / immunology
Remission Induction / methods
Sezary Syndrome / blood
Sezary Syndrome / drug therapy*
Sezary Syndrome / immunology
Skin Neoplasms / blood
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
T-Lymphocytes, Regulatory / drug effects
T-Lymphocytes, Regulatory / immunology
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
CCR4 protein, human
Receptors, CCR4
mogamulizumab